International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 5 , Pages 1439-1444 , April 2010

Total Androgen Blockade Versus a Luteinizing Hormone–Releasing Hormone Agonist Alone in Men With High-Risk Prostate Cancer Treated With Radiotherapy

Presented in part at the American Society of Clinical Oncology 2009 Genitourinary Cancers Symposium, February 26–28, 2009, Orlando, FL.

  • Akash Nanda, M.D., Ph.D.

      Affiliations

    • Harvard Radiation Oncology Program, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA
    • Corresponding Author InformationReprint requests to: Akash Nanda, M.D., Ph.D., Harvard Radiation Oncology Program, Brigham and Women's Hospital, 75 Francis Street, ASB1 L2, Boston, MA 02115. Tel: (617) 732-6310; Fax: (617) 975-0932
    • ,
  • Ming-Hui Chen, Ph.D.

      Affiliations

    • Department of Statistics, University of Connecticut, Storrs, CT
    • ,
  • Brian J. Moran, M.D.

      Affiliations

    • Prostate Cancer Foundation of Chicago, Westmont, IL
    • ,
  • Michelle H. Braccioforte, B.S.

      Affiliations

    • Prostate Cancer Foundation of Chicago, Westmont, IL
    • ,
  • Daniel Dosoretz, M.D.

      Affiliations

    • 21st Century Oncology, Fort Myers, FL
    • ,
  • Sharon Salenius, M.P.H.

      Affiliations

    • 21st Century Oncology, Fort Myers, FL
    • ,
  • Michael Katin, M.D.

      Affiliations

    • 21st Century Oncology, Fort Myers, FL
    • ,
  • Rudi Ross, B.S.

      Affiliations

    • 21st Century Oncology, Fort Myers, FL
    • ,
  • Anthony V. D'Amico, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA

Received 13 January 2009 ,Revised 12 February 2009 ,Accepted 23 March 2009.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  2. Cooperberg MR, Cowan J, Broering JM, et al. High-risk prostate cancer in the United States, 1990-2007. World J Urol. 2008;26:211–218
  3. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005;6:841–850
  4. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243–1252
  5. D'Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA. 2004;292:821–827
  6. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet. 2002;360:103–106
  7. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61:1285–1290
  8. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8:475–487
  9. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008;26:2497–2504
  10. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321:419–424
  11. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036–1042
  12. D'Amico AV, Chen MH, Renshaw AA, et al. Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Oncol. 2008;26:2979–2983
  13. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–748
  14. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509
  15. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  16. Klein JP, Moeschberger ML. Survival analysis. New York: Springer-Verlag; 1997;
  17. Zelefsky MJ, Yamada Y, Fuks Z, et al. Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys. 2008;71:1028–1033
  18. Cahlon O, Zelefsky MJ, Shippy A, et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys. 2008;71:330–337
  19. Zelefsky MJ, Chan H, Hunt M, et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006;176:1415–1419
  20. Zelefsky MJ, Marion C, Fuks Z, et al. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy. J Urol. 2003;170:1828–1832
  21. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53:1111–1116
  22. Ritter M. Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer. Semin Radiat Oncol. 2008;18:249–256
  23. Roach M, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21:1904–1911
  24. Pommier P, Chabaud S, Lagrange JL, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol. 2007;25:5366–5373
  25. Lawton CA, DeSilvio M, Roach M, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys. 2007;69:646–655
  26. Wirth MP, See WA, McLeod DG, et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: Results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol. 2004;172:1865–1870
  27. Thole Z, Manso G, Salgueiro E, et al. Hepatotoxicity induced by antiandrogens: A review of the literature. Urol Int. 2004;73:289–295
  28. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–1261
  29. Wu AK, Cooperberg MR, Sadetsky N, et al. Health related quality of life in patients treated with multimodal therapy for prostate cancer. J Urol. 2008;180:2415–2422discussion 2422
  30. Dicker AP. The safety and tolerability of low-dose irradiation for the management of gynaecomastia caused by antiandrogen monotherapy. Lancet Oncol. 2003;4:30–36
  31. D'Amico AV, Kantoff PW, Chen MH. Aspirin and hormone therapy for prostate cancer. N Engl J Med. 2007;357:2737–2738

 Conflict of interest: none.

PII: S0360-3016(09)00470-2

doi: 10.1016/j.ijrobp.2009.03.034

International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 5 , Pages 1439-1444 , April 2010

Article Tools

* Image Usage & Resolution